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Purpose/Objective: Intensity-modulated radiotherapy (IMRT) is being 
explored in various pelvic malignancies in an effort to mitigate 
treatment-related toxicity. Moreover, IMRT allows simultaneous 
differential dose delivery to multiple tumor targets (Simultaneous 
Integrated Boost, SIB), obviating sequential treatment of an initial 
volume with a subsequent boost. In addition to the convenience of a 
shortened treatment duration, theoretical benefits exist for tumor 
control too, due to hypofractionationed schedule.Our purpose is to 
evaluate the toxicity of pelvic IMRT with hypofractionated 
simultaneous integrated boost (SIB) to the prostate for patients with 
high-risk prostate cancer. 
Materials and Methods: A prospective Phase II study was initiated at 
the end of 2008. The study involved 41 consecutive patients treated 
definitively with pelvic SIB-IMRT, all of whom also received androgen 
suppression. The IMRT plans were designed to deliver 67.5 Gy in 25 
fractions (2.7 Gy/fraction) to the prostate while simultaneously 
delivering 56.25 Gy (2.25 Gy/fraction) to the seminal vesicles and 50 
Gy (2 Gy/fraction) to the pelvic lymph nodes. All subjects underwent 
ultrasound-guided transrectal placement of 3 gold intraprostatic 
fiducial markers. Daily on-line image guidance adjustments were 
made according to the positions of the fiducial markers.Acute and late 
genitourinary (GU) and gastrointestinal (GI) toxicities were scored 
according to the Radiation Therapy Oncology Group (RTOG) grading 
system.  
Results: Fiducial marker placement proceeded without complications. 
Acute GU toxicity manifested in 12 patients (29%) as grade 1 or 2 
urethritis. No patients developed urinary retention and episode of 
gross hematuria. Acute GI toxicity manifested in 5 patients (12%) as 
grade 1 or 2. No cases of rectal bleeding were observed. With a 
follow-up time ranging from 6 to 46 months, no late bladder and 
rectal complications have been observed so far.  
Conclusions: Pelvic IMRT with hypofractionated SIB to prostate was 
well tolerated in this study, with low rates of Grade 2 acute and late 
toxicity. SIB-IMRT combines pelvic radiotherapy and hypofractionation 
to the primary site and offers an accelerated approach to treating 
high-risk disease. Additional follow-up is necessary to fully define the 
long-term toxicity after hypofractionated, whole pelvic treatment 
combined with androgen suppression. 
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Purpose/Objective: Aim of this study was to test dosimetric 
parameters able to predict possible acute Genito-Urinary (GU) toxicity 
in prostate cancer patients treated with Simultaneous Integrated 
Boost (SIB). 
Materials and Methods: A prospective study was performed between 
January 2011 and March 2012 in our Institution enrolling prostate 
cancer patients. Radiotherapy was performed with volumetric Arc 
therapy technique by Linear Accelerator. The Clinical Target Volume, 
irradiated by SIB-IMRT Technique, included: prostate (CTV1, total 
dose of 80 Gy) and seminal vesicles (CTV2, total dose of 72 Gy) in 
forty fractions. We collected a series of CBCT scans during patients’ 
treatment time, and the first five was used for a treatment 
replanning. For the analysis of the GU toxicity, we divided patients 
into 2 groups: group A, patients without acute toxicity; group B 
patients with acute toxicity of any grade. Follow-up was carried out in 
our Department. Toxicity was graded according to the RTOG criteria. 
The correlations between acute GU toxicity and bladder dosimetric 
parameters were tested through logistic models. 
Results: 45 patients were included and had a total of 845 CBCT scans. 
Difference between mean PTV1 (prostate) vs PTV1r was statistically 
significant (p<0,0001). Difference between mean PTV2 (seminal 
vesicles) and PTV2r was not statistically significant (p<0,42). Bladder 
toxicity data were collected in 39/45 (87%) patients. Mean delivered 
doses of each of the 2 groups were compared: they were significantly 
higher in group B (group A 23.89 Gy vs group B 42.76 Gy, p=0,02). The 
area under the curve (AUC) of the mean dose/volume graph, traced 
for each grade of toxicity, was clear correlated with the grade of 
toxicity. 
For a dose of 25 Gy, the mean dose curve of G0 toxicity was more 
distant from the other curves G1-2-3: the median V25 was lower for 
group A (38,89%) against the value of group B (67,87%; p= 0,0085). A 
V25>50% might express the 80% of probability to envelope bladder 
toxicity of any grade (AUC =0,793, sensitivity of 73,33 and specificity 
of 88,89; p=0,0035). A dose-reduction method was used to simplify 
the evaluation of the toxicity, that is the Equivalent Uniform Dose 
(EUD). The EUD was significantly higher in patients with GU toxicity 
(group A 25.10 Gy vs group B 42.13, p=0.02). We built up a DVH-
reduction model based on estimated complication probability (NTCP) 
under EUD of the bladder: patients were distributed on or close to an 
S slope showing that TCD50 was 18 Gy. 
  
Conclusions: IGRT is one method that may reduce toxicity whilst 
maintaining high delivered treatment doses and personalizing 
treatment plans. Bladder mean dose and V25 correlate with acute GU 
toxicity and could better optimize planning procedures in treatment 
validation. Further studies with bigger series are still needed to 
confirm these finding. 
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Purpose/Objective: PSA doubling time (PSADT) has a recognized role 
in patients (pts) candidates to salvage radiotherapy (SRT) for a 
biochemical recurrence (BR) after radical prostatectomy (RP). Its role 
and the most widely accepted cut-off (10-12 months) discriminating 
between more likely local relapse and systemic progression were 
retrospectively addressed in pts typically undergoing SRT with PSA 
values at SRT much greater than those currently suggested. The study 
was aimed at investigating its reliability and ideal cut-off in pts 
candidates to very timely SRT. 
Materials and Methods: The study included 200 node-negative pts 
who received SRT for BR after RP between 1994 and 2010. BR was 
defined as the first of two or more consecutive and increasing PSA 
values >0.20 ng/mL after RP. PSADT was computed based on an 
increasing set of hormono-naïve PSA values starting from the first 
value ≥0.10 ng/mL up to the beginning of SRT (overall PSADT). PSADT 
was also computed at 3, 6, 9, 12, 18, 24 months from the first 
observation ≥0.10 ng/mL, or on 2, 3, 4, 5, 6 consequent 
measurements, when available. Biochemical relapse-free survival 
(bRFS) after SRT was considered as primary endpoint and was set as 
the time from the beginning of SRT to PSA failure after SRT (i.e. a 
single PSA >0.20 ng/mL after an SRT-induced nadir or an increase of 
serum PSA despite SRT). 
Results: After a median follow-up of 80.8 months, 44 pts (22%) 
experienced a PSA failure after SRT (33 within 5-years). The median 
overall PSADT was 8.18 months, based on a median of 4 PSA 
observations. Cox regression analysis selected as significant predictors 
for bRFS: Gleason score (2-6 vs 7-10), PSA at SRT, dose of RT, overall 
PSADT and time from RP to the first post-RP PSA value ≥0.10 ng/mL. 
